A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
Wei-Xiong Xia,Xing Lv,Hu Liang,Guo-Ying Liu,Rui Sun,Qi Zeng,Si-Wei Li,Hao-Yuan Mo,Fei Han,Dong-Hua Luo,Qing Liu,Meng-Yun Shi,Yan-Fang Ye,Jing Yang,Liang-Ru Ke,Meng-Yun Qiang,Wen-Ze Qiu,Ya-Hui Yu,Kui-Yuan Liu,Xin-Jun Huang,Wang-Zhong Li,Shu-Hui Lv,Zhuo-Chen Cai,Jing-Jing Miao,Ling Guo,Ming-Yuan Chen,Ka-Jia Cao,Lin Wang,Chong Zhao,Pei-Yu Huang,Qiu-Yan Chen,Yi-Jun Hua,Lin-Quan Tang,Chao-Nan Qian,Hai-Qiang Mai,Xiang Guo,Yan-Qun Xiang
DOI: https://doi.org/10.1158/1078-0432.ccr-20-4532
IF: 13.801
2021-06-03
Clinical Cancer Research
Abstract:Abstract Purpose: Previous studies suggest that a cumulative cisplatin dose of 200 mg/m2 might be adequate in the intensity-modulated radiation therapy (IMRT) era for locoregionally advanced nasopharyngeal carcinoma (LANPC). However, two cycles of once-every-3-weeks cisplatin at 100 mg/m2 has never been prospectively compared with standard once-a-week cisplatin regimen. Patients and Methods: This trial was conducted at three hospitals from 2011 to 2016. Patients who met the eligibility criteria were recruited (ChiCTR-TRC-12001979) and randomly assigned (1:1) via a computer-generated sequence to receive once-every-3-weeks cisplatin at 100 mg/m2 for two cycles or once-a-week cisplatin at 40 mg/m2 for six cycles concurrently with IMRT. Primary endpoint was failure-free survival and between-group absolute difference of 10% as the noninferiority margin. Results: A total of 510 patients were enrolled. Median follow-up time was 58.3 months with 85.4% of 3-year failure-free survival in the once-every-3-weeks group and 85.6% in the once-a-week group. An absolute difference of −0.2% (95% confidence interval, −6.3 to 5.9; Pnoninferiority = 0.0016). Acute toxicities of grade 3 or higher occurred in 55.8% in the once-every-3-weeks group and 66.3% in the once-a-week group (P = 0.015). The most common acute toxicities were hematologic abnormalities, including leukopenia (16% vs. 27%; P = 0.0022) and thrombocytopenia (1% vs. 5%; P = 0.015). The late grade 3–4 auditory loss rate was significantly lower in the once-every-3-weeks group than the once-a-week group (6% vs. 13%; P = 0.0039). Conclusions: Once-every-3-weeks cisplatin as concurrent chemoradiotherapy is noninferior to once-a-week cisplatin in the treatment efficacy in the LANPC. Although both regimens are well tolerated, severe acute toxicities and late-onset auditory loss are higher in the once-a-week group.
oncology